{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T13:02:35Z","timestamp":1793106155944,"version":"4.5.0"},"reference-count":104,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003093","name":"Malaysia Ministry of Higher Education","doi-asserted-by":"publisher","award":["FRGS\/1\/2020\/SKK0\/USM\/02\/24"],"award-info":[{"award-number":["FRGS\/1\/2020\/SKK0\/USM\/02\/24"]}],"id":[{"id":"10.13039\/501100003093","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["amjmedsci.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of the Medical Sciences"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.amjms.2025.10.012","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T23:27:02Z","timestamp":1761089222000},"page":"188-199","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Navigating the landscape of hepatitis B virus reactivation in HBsAg-positive and HBsAg-negative resolved infections: Current insights and future directions"],"prefix":"10.1016","volume":"371","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9825-7995","authenticated-orcid":false,"given":"Lidawani","family":"Lambuk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aina Akmal Mohd","family":"Noor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatmawati","family":"Lambuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuan Noorkorina Tuan","family":"Kub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Zulfiqah","family":"Sadikan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norhayati","family":"Yusop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohimah","family":"Mohamud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nik Haszroel Hysham","family":"Nik Hashim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjms.2025.10.012_bib0001","series-title":"Hepatitis B Virus in Human Diseases","first-page":"187","article-title":"Global epidemiology of Hepatitis B Virus infection","author":"Lavanchy","year":"2016"},{"key":"10.1016\/j.amjms.2025.10.012_bib0002","unstructured":"World Health Organization (WHO). Global hepatitis report 2024: action for access in low- and middle-income countries, https:\/\/www.who.int\/publications\/i\/item\/9789240091672; 2024 [accessed 8.12.2024]."},{"key":"10.1016\/j.amjms.2025.10.012_bib0003","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.3390\/microorganisms11051140","article-title":"Vertical transmission of Hepatitis B virus - an update","volume":"11","author":"di Filippo Villa","year":"2023","journal-title":"Microorganisms"},{"key":"10.1016\/j.amjms.2025.10.012_bib0004","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S2468-1253(23)00197-8","article-title":"Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study","volume":"8","author":"Razavi Shearer","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.amjms.2025.10.012_bib0005","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/hep4.1460","article-title":"Hepatitis B and pregnancy: virologic and immunologic characteristics","volume":"4","author":"Joshi","year":"2020","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.amjms.2025.10.012_bib0006","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ejim.2022.11.024","article-title":"Patients treated with rituximab are poorly screened for hepatitis B infection: data from a low-incidence country","volume":"108","author":"Brakenhoff","year":"2023","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.amjms.2025.10.012_bib0007","doi-asserted-by":"crossref","DOI":"10.1177\/2040206620921331","article-title":"Nucleos(t)ide analogues and Hepatitis B virus-related hepatocellular carcinoma: a literature review","volume":"28","author":"Abd El Aziz","year":"2020","journal-title":"Antivir Chem Chemother"},{"key":"10.1016\/j.amjms.2025.10.012_bib0008","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2147\/JHC.S221187","article-title":"Hepatocellular carcinoma mechanisms associated with chronic HCV infection and the impact of direct-acting antiviral treatment","volume":"7","author":"Dash","year":"2020","journal-title":"J Hepatocell Carcinoma"},{"key":"10.1016\/j.amjms.2025.10.012_bib0009","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1053\/j.gastro.2017.02.009","article-title":"Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions","volume":"152","author":"Loomba","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.amjms.2025.10.012_bib0010","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.770124","article-title":"Hepatitis B virus reactivation associated with therapeutic interventions","volume":"8","author":"Chang","year":"2022","journal-title":"Front Med"},{"key":"10.1016\/j.amjms.2025.10.012_bib0011","first-page":"1560","article-title":"Update on prevention, diagnosis, and treatment of Chronic Hepatitis B: AASLD 2018 Hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.amjms.2025.10.012_bib0012","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1080\/17474124.2020.1774364","article-title":"Hepatitis B reactivation: diagnosis and management","volume":"14","author":"Huang","year":"2020","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.amjms.2025.10.012_bib0013","doi-asserted-by":"crossref","first-page":"30","DOI":"10.7326\/M15-1121","article-title":"Hepatitis B virus reactivation and prophylaxis during solid tumor chemotherapy","volume":"164","author":"Sonali","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.amjms.2025.10.012_bib0014","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3324\/haematol.2018.210252","article-title":"Reactivation of hepatitis B virus infection in patients with hematologic disorders","volume":"104","author":"Bo","year":"2019","journal-title":"Haematol"},{"key":"10.1016\/j.amjms.2025.10.012_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.bjid.2023.103703","article-title":"Clinical study of hepatitis B vaccine in achieving hepatitis B surface antibody seroconversion in patients with functional cure","volume":"27","author":"Liu","year":"2023","journal-title":"Braz J Infect Dis"},{"key":"10.1016\/j.amjms.2025.10.012_bib0016","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.3390\/v14081780","article-title":"Hepatitis B surface antibody (Anti-HBs) kinetics during Rituximab chemotherapy and performance of Hepatitis B vaccine before immunosuppression: two prospective studies","volume":"14","author":"JMd","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.amjms.2025.10.012_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhlto.2023.100018","article-title":"Hepatitis B virus reactivation in hepatitis B core antibody positive lung transplant recipients","volume":"3","author":"Fernandez-Garcia","year":"2024","journal-title":"JHLT Open"},{"key":"10.1016\/j.amjms.2025.10.012_bib0018","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/bjh.19140","article-title":"Stratified management based on surface antibody for the prevention of hepatitis B virus reactivation in lymphoma patients","volume":"203","author":"Liu","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.amjms.2025.10.012_bib0019","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3390\/jpm11040267","article-title":"Management of Hepatitis B Virus reactivation in malignant lymphoma prior to immunosuppressive treatment","volume":"11","author":"Tsai","year":"2021","journal-title":"J Pers Med"},{"key":"10.1016\/j.amjms.2025.10.012_bib0020","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1182\/blood-2023-173461","article-title":"Recurrence of HBV reactivation after allogeneic hematopoietic transplantation in recipients with resolved HBV infection: a nation-wide multicenter retrospective study","volume":"142","author":"Onozawa","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.amjms.2025.10.012_bib0021","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s40264-024-01399-4","article-title":"Consensus Guidelines: best practices for the prevention, detection and management of Hepatitis B virus reactivation in clinical trials with immunosuppressive\/immunomodulatory therapy","volume":"47","author":"Cohen","year":"2024","journal-title":"Drug Saf"},{"key":"10.1016\/j.amjms.2025.10.012_bib0022","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.00049","article-title":"Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus","volume":"1","author":"Yan","year":"2012","journal-title":"ELife"},{"key":"10.1016\/j.amjms.2025.10.012_bib0023","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1053\/j.gastro.2013.12.024","article-title":"Hepatitis B and D viruses exploit sodium taurocholate Co-transporting polypeptide for species-specific entry into hepatocytes","volume":"146","author":"Ni","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.amjms.2025.10.012_bib0024","article-title":"Assembly and release of Hepatitis B virus","volume":"5","author":"Selzer","year":"2015","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.amjms.2025.10.012_bib0025","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1038\/s41467-021-21850-9","article-title":"Hepatitis B virus cccDNA is formed through distinct repair processes of each strand","volume":"12","author":"Wei","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.amjms.2025.10.012_bib0026","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.jhep.2018.08.012","article-title":"Hepatitis B virus genome recycling and de novo secondary infection events maintain stable cccDNA levels","volume":"69","author":"Ko","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.amjms.2025.10.012_bib0027","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1053\/j.gastro.2006.01.001","article-title":"Hepatitis B Virus replication is regulated by the acetylation status of Hepatitis B Virus cccDNA-bound H3 and H4 histones","volume":"130","author":"Pollicino","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.amjms.2025.10.012_bib0028","doi-asserted-by":"crossref","DOI":"10.5812\/hepatmon.28751","article-title":"Simple and reliable method to quantify the Hepatitis B viral load and replicative capacity in liver tissue and blood leukocytes","volume":"16","author":"Minosse","year":"2016","journal-title":"Hepat Mon"},{"key":"10.1016\/j.amjms.2025.10.012_bib0029","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1053\/j.gastro.2005.03.009","article-title":"Intrahepatic Hepatitis B virus covalently closed circular DNA can Be a predictor of sustained response to therapy","volume":"128","author":"Sung","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.amjms.2025.10.012_bib0030","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.coviro.2018.01.007","article-title":"Role of HBx in hepatitis B virus persistence and its therapeutic implications","volume":"30","author":"Slagle","year":"2018","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.amjms.2025.10.012_bib0031","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/1096-9071(200011)62:3<299::AID-JMV1>3.0.CO;2-0","article-title":"Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors","volume":"62","author":"Yeo","year":"2000","journal-title":"J Med Virol"},{"key":"10.1016\/j.amjms.2025.10.012_bib0032","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1053\/j.gastro.2008.07.008","article-title":"HBsAg seroclearance in chronic Hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma","volume":"135","author":"Yuen","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.amjms.2025.10.012_bib0033","first-page":"92","article-title":"Hepatitis B Virus infection during pregnancy: transmission and prevention","volume":"3","author":"Navabakhsh","year":"2011","journal-title":"Middle East J Dig Dis"},{"key":"10.1016\/j.amjms.2025.10.012_bib0034","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003490","article-title":"CD40 Activation rescues antiviral CD8+ T cells from PD-1-mediated exhaustion","volume":"9","author":"Isogawa","year":"2013","journal-title":"PLOS Pathog"},{"key":"10.1016\/j.amjms.2025.10.012_bib0035","doi-asserted-by":"crossref","first-page":"6359","DOI":"10.1128\/JVI.75.14.6359-6366.2001","article-title":"Hepatitis B virus core antigen binds and activates naive Human B cells In vivo: studies with a Human PBL-NOD\/SCID mouse model","volume":"75","author":"Cao","year":"2001","journal-title":"J Virol"},{"key":"10.1016\/j.amjms.2025.10.012_bib0036","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","author":"Lampertico","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.amjms.2025.10.012_bib0037","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol Int"},{"key":"10.1016\/j.amjms.2025.10.012_bib0038","doi-asserted-by":"crossref","DOI":"10.5812\/jjm.21444","article-title":"Comparison of serum Hepatitis B Virus DNA and HBsAg levels between HBeAg-negative and HBeAg-positive chronic Hepatitis B patients","volume":"8","author":"Keshvari","year":"2015","journal-title":"Jundishapur J Microbiol"},{"key":"10.1016\/j.amjms.2025.10.012_bib0039","first-page":"13","article-title":"Hepatitis B functional cure and immune response","author":"Zheng","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.amjms.2025.10.012_bib0040","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1053\/j.gastro.2014.10.038","article-title":"American Gastroenterological Association Institute Technical Review on prevention and treatment of Hepatitis B virus reactivation during immunosuppressive drug therapy","volume":"148","author":"Perrillo","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.amjms.2025.10.012_bib0041","doi-asserted-by":"crossref","first-page":"3736","DOI":"10.1200\/JCO.2014.56.7081","article-title":"Hepatitis B reactivation in patients with previous Hepatitis B virus exposure undergoing Rituximab-containing chemotherapy for lymphoma: a prospective study","volume":"32","author":"Seto","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.amjms.2025.10.012_bib0042","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3904\/kjim.2007.22.4.237","article-title":"Hepatitis B reactivation during adjuvant anthracycline-based chemotherapy in patients with breast cancer: a single institution's experience","volume":"22","author":"Kim","year":"2007","journal-title":"Korean J Intern Med"},{"key":"10.1016\/j.amjms.2025.10.012_bib0043","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1136\/annrheumdis-2021-221650","article-title":"Average corticosteroid dose and risk for HBV reactivation and hepatitis flare in patients with resolved hepatitis B infection","volume":"81","author":"Zhenyu","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.amjms.2025.10.012_bib0044","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/jvh.12402","article-title":"Hepatitis B reactivation in HBsAg-negative\/HBcAb-positive patients receiving rituximab for lymphoma: a meta-analysis","volume":"22","author":"Mozessohn","year":"2015","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.amjms.2025.10.012_bib0045","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.antiviral.2015.08.005","article-title":"Metabolism and function of hepatitis B virus cccDNA: implications for the development of cccDNA-targeting antiviral therapeutics","volume":"122","author":"Guo","year":"2015","journal-title":"Antiviral Res"},{"key":"10.1016\/j.amjms.2025.10.012_bib0046","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40880-015-0015-9","article-title":"Hepatitis B virus reactivation and hepatitis in diffuse large B-cell lymphoma patients with resolved hepatitis B receiving rituximab-containing chemotherapy: risk factors and survival","volume":"34","author":"Chen","year":"2015","journal-title":"Chin J Cancer"},{"key":"10.1016\/j.amjms.2025.10.012_bib0047","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/1756-185X.14034","article-title":"Risk of hepatitis B reactivation in patients receiving anti-tumor necrosis factor-\u03b1 therapy","volume":"24","author":"Fidan","year":"2021","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.amjms.2025.10.012_bib0048","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1053\/j.gastro.2014.06.043","article-title":"Roles for chemokines in liver disease","volume":"147","author":"Marra","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.amjms.2025.10.012_bib0049","doi-asserted-by":"crossref","first-page":"6405","DOI":"10.3892\/mmr.2015.4312","article-title":"Associations between activation-induced cytidine deaminase\/apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like cytidine deaminase expression, hepatitis B virus (HBV) replication and HBV-associated liver disease (Review)","volume":"12","author":"He","year":"2015","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.amjms.2025.10.012_bib0050","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13099-021-00421-9","article-title":"Potential capacity of interferon-\u03b1 to eliminate covalently closed circular DNA (cccDNA) in hepatocytes infected with hepatitis B virus","volume":"13","author":"Wang","year":"2021","journal-title":"Gut Pathog"},{"key":"10.1016\/j.amjms.2025.10.012_bib0051","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.3390\/v11111077","article-title":"HBV infection in HIV-driven immune suppression","volume":"11","author":"Sarmati","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.amjms.2025.10.012_bib0052","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/S2468-1253(18)30002-5","article-title":"Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis","volume":"3","author":"M\u00fccke","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.amjms.2025.10.012_bib0053","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/hep.29022","article-title":"Hepatitis B reactivation in occult viral carriers undergoing hematopoietic stem cell transplantation: a prospective study","volume":"65","author":"Seto","year":"2017","journal-title":"Hepatol"},{"key":"10.1016\/j.amjms.2025.10.012_bib0054","doi-asserted-by":"crossref","first-page":"385","DOI":"10.4254\/wjh.v8.i8.385","article-title":"Management of hepatitis B reactivation in immunosuppressed patients: an update on current recommendations","volume":"8","author":"Bessone","year":"2016","journal-title":"World J Hepatol"},{"key":"10.1016\/j.amjms.2025.10.012_bib0055","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X20912646","article-title":"Reactivation of hepatitis B virus infection in rheumatic diseases: risk and management considerations","volume":"12","author":"Koutsianas","year":"2020","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.amjms.2025.10.012_bib0056","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1182\/blood.V99.7.2324","article-title":"High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation","volume":"99","author":"Lau","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.amjms.2025.10.012_bib0057","doi-asserted-by":"crossref","first-page":"209","DOI":"10.13105\/wjma.v7.i5.209","article-title":"Hepatitis B reactivation in patients with hepatitis B core antibody positive and surface antigen negative on immunosuppressants","volume":"7","author":"Wu","year":"2019","journal-title":"World J Meta-Anal"},{"key":"10.1016\/j.amjms.2025.10.012_bib0058","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1002\/jmv.24423","article-title":"High titers of anti-HBs prevent rituximab-related viral reactivation in resolved hepatitis B patient with non-Hodgkin's lymphoma","volume":"88","author":"Cho","year":"2016","journal-title":"J Med Virol"},{"key":"10.1016\/j.amjms.2025.10.012_bib0059","first-page":"6543","article-title":"The combination of anti\u2011HBc and anti\u2011HBs levels is a useful predictor of the development of chemotherapy\u2011induced reactivation in lymphoma patients with resolved HBV infection","volume":"14","author":"Matsubara","year":"2017","journal-title":"Oncol Lett"},{"key":"10.1016\/j.amjms.2025.10.012_bib0060","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/hep.29082","article-title":"Role of surface antibody in hepatitis B reactivation in patients with resolved infection and hematologic malignancy: a meta-analysis","volume":"66","author":"Paul","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.amjms.2025.10.012_bib0061","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1053\/j.gastro.2014.10.039","article-title":"American Gastroenterological Association Institute guideline on the prevention and treatment of Hepatitis B virus reactivation during immunosuppressive drug therapy","volume":"148","author":"Reddy","year":"2015","journal-title":"Gastroenterol"},{"key":"10.1016\/j.amjms.2025.10.012_bib0062","doi-asserted-by":"crossref","DOI":"10.3748\/wjg.v21.i42.12083","article-title":"Management of hepatitis B virus infection after liver transplantation","volume":"21","author":"Jim\u00e9nez-P\u00e9rez","year":"2015","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.amjms.2025.10.012_bib0063","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.3390\/v15051037","article-title":"The role of antiviral prophylaxis in preventing HBV and HDV recurrence in the setting of liver transplantation","volume":"15","author":"Battistella","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.amjms.2025.10.012_bib0064","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.livres.2019.03.002","article-title":"Risk assessment and management of hepatitis B reactivation from direct-acting antivirals for hepatitis C","volume":"3","author":"Whitsett","year":"2019","journal-title":"Liver Res"},{"key":"10.1016\/j.amjms.2025.10.012_bib0065","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.cld.2020.04.002","article-title":"Hepatitis B virus reactivation: what is the issue, and how should it Be managed?","volume":"24","author":"Ekpanyapong","year":"2020","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.amjms.2025.10.012_bib0066","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.clinre.2014.07.010","article-title":"Prophylactic lamivudine to improve the outcome of HBsAg-positive lymphoma patients during chemotherapy: a systematic review and meta-analysis","volume":"39","author":"Li","year":"2015","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.amjms.2025.10.012_bib0067","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1002\/phar.2340","article-title":"Hepatitis B virus reactivation: risk factors and current management strategies","volume":"39","author":"Smalls","year":"2019","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.amjms.2025.10.012_bib0068","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1080\/14787210.2016.1220831","article-title":"Comparative efficacy of oral nucleotide analogues for the prophylaxis of hepatitis B virus recurrence after liver transplantation: a network meta-analysis","volume":"14","author":"Zheng","year":"2016","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.amjms.2025.10.012_bib0069","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s10620-017-4850-1","article-title":"Practice patterns in Hepatitis B virus screening before cancer chemotherapy in a major US hospital network","volume":"63","author":"Kwak","year":"2018","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.amjms.2025.10.012_bib0070","doi-asserted-by":"crossref","first-page":"e6528","DOI":"10.1097\/MD.0000000000006528","article-title":"Using health-system-wide data to understand hepatitis B virus prophylaxis and reactivation outcomes in patients receiving rituximab","volume":"96","author":"Schmajuk","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.amjms.2025.10.012_bib0071","doi-asserted-by":"crossref","first-page":"7365","DOI":"10.1038\/s41598-022-10665-3","article-title":"Cost-effectiveness of managing HBV reactivation in patients with resolved HBV infection treated with anti-CD20 antibody for B-cell non-hodgkin lymphoma","volume":"12","author":"Fujita","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.amjms.2025.10.012_bib0072","first-page":"1","article-title":"Cost-effectiveness analysis of hepatitis B virus screening and management in patients with hematologic or solid malignancies anticipating immunosuppressive cancer therapy","volume":"3","author":"Hwang","year":"2019","journal-title":"JCO Clin Can Inform"},{"key":"10.1016\/j.amjms.2025.10.012_bib0073","doi-asserted-by":"crossref","first-page":"e568","DOI":"10.1016\/S2214-109X(16)30101-2","article-title":"Cost-effectiveness of community-based screening and treatment for chronic hepatitis B in the Gambia: an economic modelling analysis","volume":"4","author":"Nayagam","year":"2016","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.amjms.2025.10.012_bib0074","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ijid.2015.04.020","article-title":"Seroprevalence of chronic hepatitis B, as determined from dried blood spots, among children and their mothers in central Lao People's Democratic Republic: a multistage, stratified cluster sampling survey","volume":"36","author":"Komada","year":"2015","journal-title":"Int J Infect Control Dis"},{"key":"10.1016\/j.amjms.2025.10.012_bib0075","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1128\/JCM.02980-14","article-title":"Validation of rapid point-of-care (POC) tests for detection of Hepatitis B surface antigen in field and laboratory settings in the Gambia, Western Africa","volume":"53","author":"Njai","year":"2015","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.amjms.2025.10.012_bib0076","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1007\/s11606-022-07806-9","article-title":"Prevention of Hepatitis B reactivation in patients receiving immunosuppressive therapy: a case series and appraisal of society guidelines","volume":"38","author":"Etienne","year":"2023","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.amjms.2025.10.012_bib0077","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1053\/j.gastro.2018.11.037","article-title":"New and old biomarkers for diagnosis and management of chronic Hepatitis B virus infection","volume":"156","author":"Coffin","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.amjms.2025.10.012_bib0078","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s12072-021-10239-x","article-title":"APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy","volume":"15","author":"Lau","year":"2021","journal-title":"Hepatol Int"},{"issue":"9","key":"10.1016\/j.amjms.2025.10.012_bib0079","doi-asserted-by":"crossref","DOI":"10.1002\/hep4.1238","article-title":"Preventing Hepatitis B reactivation during anti-CD20 antibody treatment in the Veterans Health Administration","volume":"2","author":"Jasmine Bullard","year":"2018","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.amjms.2025.10.012_bib0080","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.3390\/v14102229","article-title":"Assessment of adherence to clinical guidelines in patients with chronic Hepatitis B","volume":"14","author":"Katwaroe","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.amjms.2025.10.012_bib0081","first-page":"1425","article-title":"Guidelines for the prevention and treatment of chronic Hepatitis B (version 2022)","volume":"11","author":"You","year":"2023","journal-title":"J Clin Transl Hepatol"},{"key":"10.1016\/j.amjms.2025.10.012_bib0082","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s12985-023-02140-w","article-title":"Hepatitis B virus reactivation in seronegative occult hepatitis B patient receiving ibrutinib therapy","volume":"20","author":"Lam","year":"2023","journal-title":"Virol J"},{"key":"10.1016\/j.amjms.2025.10.012_bib0083","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/rmv.322","article-title":"Hepatitis B virus (HBV) reactivation after cytotoxic or immunosuppressive therapy\u2014Pathogenesis and management","volume":"11","author":"Xunrong","year":"2001","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.amjms.2025.10.012_bib0084","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12879-020-05025-3","article-title":"Existence of hepatitis B virus surface protein mutations and other variants: demand for hepatitis B infection control in Cambodia","volume":"20","author":"Ko","year":"2020","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.amjms.2025.10.012_bib0085","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a021550","article-title":"Hepatitis D virus coinfection and superinfection","volume":"4","author":"Negro","year":"2014","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.amjms.2025.10.012_bib0086","doi-asserted-by":"crossref","first-page":"696","DOI":"10.3389\/fgene.2019.00696","article-title":"Host genetic determinants of hepatitis B virus infection","volume":"10","author":"Zhang","year":"2019","journal-title":"Front Genet"},{"key":"10.1016\/j.amjms.2025.10.012_bib0087","doi-asserted-by":"crossref","first-page":"5769","DOI":"10.12998\/wjcc.v9.i21.5769","article-title":"Prevention of hepatitis B reactivation in patients requiring chemotherapy and immunosuppressive therapy","volume":"9","author":"Shih","year":"2021","journal-title":"World J Clin Cases"},{"key":"10.1016\/j.amjms.2025.10.012_bib0088","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/hep.28552","article-title":"Serum levels of hepatitis B surface antigen and DNA can predict inactive carriers with low risk of disease progression","volume":"64","author":"Liu","year":"2016","journal-title":"Hepatol"},{"key":"10.1016\/j.amjms.2025.10.012_bib0089","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s12072-015-9692-3","article-title":"Prevention and management of hepatitis B virus reactivation in cancer patients","volume":"10","author":"Cheung","year":"2016","journal-title":"Hepatol Int"},{"key":"10.1016\/j.amjms.2025.10.012_bib0090","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/j.1872-034X.2012.00998.x","article-title":"Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy","volume":"42","author":"Oketani","year":"2012","journal-title":"Hepatol Res"},{"key":"10.1016\/j.amjms.2025.10.012_bib0091","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1111\/hepr.14191","article-title":"Nationwide survey of patients with acute liver failure and late-onset hepatic failure in Japan seen between 2016 and 2021","volume":"55","author":"Nakayama","year":"2025","journal-title":"Hepatol Res"},{"key":"10.1016\/j.amjms.2025.10.012_bib0092","doi-asserted-by":"crossref","first-page":"6484","DOI":"10.3748\/wjg.v22.i28.6484","article-title":"Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy","volume":"22","author":"Law","year":"2016","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.amjms.2025.10.012_bib0093","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s11901-024-00662-7","article-title":"A review of Hepatitis B reactivation risk on immunosuppressants with a focus on newer immunomodulators","volume":"23","author":"Dossaji","year":"2024","journal-title":"Curr Hepatol Rep"},{"key":"10.1016\/j.amjms.2025.10.012_bib0094","first-page":"719","article-title":"Lessons learned from chemotherapeutic and immunosuppressant induced Hepatitis B reactivation-a case series","volume":"76","author":"Nida'Ul-Huda","year":"2021","journal-title":"Med J Malaysia"},{"key":"10.1016\/j.amjms.2025.10.012_bib0095","doi-asserted-by":"crossref","first-page":"4026","DOI":"10.1007\/s10620-020-06725-1","article-title":"Risk of Hepatitis B virus reactivation in rheumatoid arthritis patients undergoing Tocilizumab-containing treatment","volume":"66","author":"Kuo","year":"2021","journal-title":"Dig Dis Sci"},{"issue":"3","key":"10.1016\/j.amjms.2025.10.012_bib0096","doi-asserted-by":"crossref","first-page":"212","DOI":"10.7861\/clinmedicine.18-3-212","article-title":"Hepatitis B virus reactivation in patients treated with immunosuppressive drugs: a practical guide for clinicians","volume":"18","author":"Koffas","year":"2018","journal-title":"Clin Med"},{"key":"10.1016\/j.amjms.2025.10.012_bib0097","doi-asserted-by":"crossref","first-page":"5769","DOI":"10.12998\/wjcc.v9.i21.5769","article-title":"Prevention of hepatitis B reactivation in patients requiring chemotherapy and immunosuppressive therapy","volume":"9","author":"Shih","year":"2021","journal-title":"World J Clin Cases"},{"key":"10.1016\/j.amjms.2025.10.012_bib0098","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.15389","article-title":"Hepatitis B virus reactivation in non-liver solid organ transplantation: incidence and risk analysis","volume":"38","author":"Chiu","year":"2024","journal-title":"Clin Transplant"},{"key":"10.1016\/j.amjms.2025.10.012_bib0099","doi-asserted-by":"crossref","first-page":"804","DOI":"10.3390\/vaccines12070804","article-title":"Hepatitis B reactivation and vaccination effectiveness after solid organ transplantation: a matched case-control study","volume":"12","author":"Lee","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.amjms.2025.10.012_bib0100","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3390\/jcm13020393","article-title":"Hepatitis B virus reactivation with immunosuppression: a hidden threat?","volume":"13","author":"Anvari","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.amjms.2025.10.012_bib0101","doi-asserted-by":"crossref","first-page":"10274","DOI":"10.3748\/wjg.v21.i36.10274","article-title":"Hepatitis B virus reactivation associated with antirheumatic therapy: risk and prophylaxis recommendations","volume":"21","author":"Mori","year":"2015","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.amjms.2025.10.012_bib0102","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1111\/hepr.13553","article-title":"Longitudinal changes of liver function and hepatitis B reactivation in COVID-19 patients with pre-existing chronic hepatitis B virus infection","volume":"50","author":"Liu","year":"2020","journal-title":"Hepatol Res"},{"key":"10.1016\/j.amjms.2025.10.012_bib0103","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.leukres.2019.05.001","article-title":"Hepatitis B reactivation during treatment of tyrosine kinase inhibitors\u2014Experience in 142 adult patients with chronic myeloid leukemia","volume":"81","author":"Wang","year":"2019","journal-title":"Leukemia Res"},{"key":"10.1016\/j.amjms.2025.10.012_bib0104","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1200\/JCO.2008.18.0182","article-title":"Hepatitis B virus reactivation in lymphoma patients with prior resolved Hepatitis B undergoing anticancer therapy with or without Rituximab","volume":"27","author":"Yeo","year":"2009","journal-title":"J Clin Onco"}],"container-title":["The American Journal of the Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962925012534?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962925012534?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T03:58:56Z","timestamp":1773287936000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002962925012534"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":104,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0002962925012534"],"URL":"https:\/\/doi.org\/10.1016\/j.amjms.2025.10.012","relation":{},"ISSN":["0002-9629"],"issn-type":[{"value":"0002-9629","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Navigating the landscape of hepatitis B virus reactivation in HBsAg-positive and HBsAg-negative resolved infections: Current insights and future directions","name":"articletitle","label":"Article Title"},{"value":"The American Journal of the Medical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjms.2025.10.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}